The academic-led, industry-partnered collaboration Equitable Breakthroughs in Medicine Development (EQBMED) has released an ...

Idorsia may have negotiated a $35 million payday ahead of a potential licensing deal for its hypertension drug Tryvio, but ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Medigene will slim its headcount by 40% and pause plans to get its first asset into the clinic in order to channel cash to ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

A federal court jury has sided with Guardant Health, which had claimed that rival cancer test developer Natera went too far ...

Acadia Pharmaceuticals has penned an exclusive licensing deal worth up to $582 million biobucks for Saniona’s neurological ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...